SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Despite preclinical and clinical evidence that SGLT2 inhibitors may be helpful in the treatment of NAFLD, evidence of their efficacy and long-term outcomes for this indication is still lacking, and further large prospective double-blind and placebo-controlled studies are needed to ultimately confirm this evidence.